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Summary
Background Uncertainty exists about the optimal schedule of adjuvant treatment of breast cancer with aromatase 
inhibitors and, to our knowledge, no trial has directly compared the three aromatase inhibitors anastrozole, 
exemestane, and letrozole. We investigated the schedule and type of aromatase inhibitors to be used as adjuvant 
treatment for hormone receptor-positive early breast cancer.
Methods FATA-GIM3 is a multicentre, open-label, randomised, phase 3 trial of six different treatments in 
postmenopausal women with hormone receptor-positive early breast cancer. Eligible patients had histologically 
confirmed invasive hormone receptor-positive breast cancer that had been completely removed by surgery, any 
pathological tumour size, and axillary nodal status. Key exclusion criteria were hormone replacement therapy, 
recurrent or metastatic disease, previous treatment with tamoxifen, and another malignancy in the previous 
10 years. Patients were randomly assigned in an equal ratio to one of six treatment groups: oral anastrozole (1 mg 
per day), exemestane (25 mg per day), or letrozole (2·5 mg per day) tablets upfront for 5 years (upfront strategy) or 
oral tamoxifen (20 mg per day) for 2 years followed by oral administration of one of the three aromatase inhibitors 
for 3 years (switch strategy). Randomisation was done by a computerised minimisation procedure stratified for 
oestrogen receptor, progesterone receptor, and HER2 status; previous chemotherapy; and pathological nodal status. 
Neither the patients nor the physicians were masked to treatment allocation. The primary endpoint was disease-
free survival. The minimum cutoff to declare superiority of the upfront strategy over the switch strategy was 
assumed to be a 2% difference in disease-free survival at 5 years. Primary efficacy analyses were done by intention 
to treat; safety analyses included all patients for whom at least one safety case report form had been completed. 
Follow-up is ongoing. This trial is registered with the European Clinical Trials Database, number 2006-004018-42, 
and ClinicalTrials.gov, number NCT00541086.
Findings Between March 9, 2007, and July 31, 2012, 3697 patients were enrolled into the study. After a median 
follow-up of 60 months (IQR 46–72), 401 disease-free survival events were reported, including 211 (11%) of 
1850 patients allocated to the switch strategy and 190 (10%) of 1847 patients allocated to upfront treatment. 5-year 
disease-free survival was 88·5% (95% CI 86·7–90·0) with the switch strategy and 89·8% (88·2–91·2) with 
upfront treatment (hazard ratio 0·89, 95% CI 0·73–1·08; p=0·23). 5-year disease-free survival was 90·0% (95% CI 
87·9–91·7) with anastrozole (124 events), 88·0% (85·8–89·9) with exemestane (148 events), and 
89·4% (87·3 to 91·1) with letrozole (129 events; p=0·24). No unexpected serious adverse reactions or treatment-
related deaths occurred. Musculoskeletal side-effects were the most frequent grade 3–4 events, reported in 
130 (7%) of 1761 patients who received the switch strategy and 128 (7%) of 1766 patients who received upfront 
treatment. Grade 1 musculoskeletal events were more frequent with the upfront schedule than with the switch 
schedule (924 [52%] of 1766 patients vs 745 [42%] of 1761 patients). All other grade 3–4 adverse events occurred in 
less than 2% of patients in either group. 
Interpretation 5 years of treatment with aromatase inhibitors was not superior to 2 years of tamoxifen followed by 
3 years of aromatase inhibitors. None of the three aromatase inhibitors was superior to the others in terms of efficacy. 
Therefore, patient preference, tolerability, and financial constraints should be considered when deciding the optimal 
treatment approach in this setting.
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Introduction
For many years, tamoxifen has been the adjuvant 
treatment of choice for postmenopausal women with 
hormone-responsive early breast cancer; 5 years of 
treatment reduces the risk of recurrence by 47% and the 
risk of death by 26%.1 However, increased incidence of 
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endometrial cancer, thromboembolic disorders, hot 
flushes, mood disorders, and vaginal symptoms have 
been reported as notable side-effects of tamoxifen.1,2
Three aromatase inhibitors, either non-steroidal 
(anastrozole and letrozole) or steroidal (exemestane), 
have been shown to improve the efficacy of adjuvant 
endocrine treatment if used in place of or sequentially 
with tamoxifen. However, all aromatase inhibitors cause 
adverse events of arthralgia, bone pain, and osteoporosis.3–9
In 2006, when the First Adjuvant Trial on All 
Aromatase Inhibitors (FATA-GIM3) was planned, 
whether aromatase inhibitors should be used upfront or 
after 2 years of tamoxifen treatment was highly debated. 
A possible beneficial effect on disease-free survival 
during the first 2 years of treatment favoured the upfront 
strategy;10 by contrast, indirect comparisons of trials 
testing the switch strategy with trials testing the upfront 
strategy suggested a greater benefit with the sequential 
strategy because of possible lower induction of drug-
resistant phenotypes.11 Additionally, musculoskeletal and 
cardiac toxicity were considered more likely to occur with 
longer exposure to aromatase inhibitors (ie, with upfront 
treatment), but, after the ATAC study3—the first large 
trial to be published in this field—the upfront strategy 
with anastrozole was regarded as standard practice. 
Simulations and modelling approaches have shown 
conflicting results, although they suggested relevant 
clinical and economic implications depending on the 
schedule used.10,11 Furthermore, whether or not 
differences existed among different types of aromatase 
inhibitors, either in terms of efficacy or side-effects, was 
uncertain because they had never been compared directly 
in a single trial.
Therefore, the FATA-GIM3 trial was planned to test 
whether or not upfront treatment with aromatase inhibitors 
was more effective than the sequential treatment approach 
and to directly compare (to our knowledge, for the first 
time) anastrozole versus exemestane versus letrozole.
Methods
Study design and participants
FATA-GIM3 is a multicentre, open-label, randomised, 
2 × 3 factorial phase 3 trial done in 76 public institutions in 
Italy. Eligible patients were postmenopausal women of any 
age with histologically confirmed invasive breast cancer 
that had been completely removed by surgery, with any 
pathological tumour size and any axillary nodal status 
according to the 2003 American Joint Committee on 
Cancer staging system.12 For women younger than 60 years, 
absence of menses for more than 1 year or follicle-
stimulating hormone concentrations within the 
postmenopausal range were required. Women who had 
previously undergone bilateral oophorectomy were also 
eligible. The primary tumour had to score positive for 
oestrogen receptor or progesterone receptor status (≥10% of 
tumour cells positive in immuno histochemistry or 
≥10 fmol/mg cytosol protein in ligand-binding assay). 
Adjuvant or neoadjuvant chemotherapy, if given, had to be 
Research in context
Evidence before this study
We searched PubMed without language restrictions up to 
Aug 30, 2017, using the search terms “early breast cancer”, 
“adjuvant treatment”, and “anastrozole or exemestane or 
letrozole” to identify meta-analyses and prospective trials of 
adjuvant endocrine treatment of postmenopausal women 
with breast cancer. We identified one Early Breast Cancer 
Trialists’ Collaborative Group (EBCTCG) meta-analysis on the 
efficacy of adjuvant treatment with tamoxifen and aromatase 
inhibitors; two international trials—the BIG1-98 study (with 
letrozole) and TEAM study (with exemestane)—comparing 
switch with upfront schedules; and two trials that did head-to-
head comparisons of anastrozole and exemestane 
(MA.27 study) or letrozole (FACE trial; node-positive patients 
only). These studies showed that tamoxifen given for 5 years 
reduced the annual risk of recurrence by 47% and the risk of 
death by 26%. Aromatase inhibitors reduced annual recurrence 
by about 30% compared with tamoxifen, and an aromatase 
inhibitor given for 5 years reduced 10-year breast cancer 
mortality by about 15% compared with 5 years of tamoxifen. 
Tamoxifen followed by letrozole was similarly effective to 
letrozole alone (BIG1-98), and tamoxifen followed by 
exemestane was similarly effective to exemestane alone 
(TEAM). Treatment with exemestane for 5 years was not better 
than anastrozole for 5 years (MA.27), and letrozole for 5 years 
was not better than anastrozole for 5 years in the treatment of 
node-positive patients (FACE).
Added value of this study
To our knowledge, no trial has used anastrozole when directly 
comparing the switch schedule with the upfront schedule, and no 
direct evidence is available that compares exemestane with 
letrozole and, more broadly, the three aromatase inhibitors 
among themselves. Thus, FATA-GIM3 contributes important data 
to the comparisons of the upfront schedule (5 years of aromatase 
inhibitors) with the switch schedule (2 years of tamoxifen 
followed by 3 years of aromatase inhibitors), and among the three 
aromatase inhibitors.
Implications of all the available evidence
The available evidence shows that the absolute difference 
between 5 years of aromatase inhibitors and 2 years of tamoxifen 
then aromatase inhibitors for 3 years is small in terms of clinical 
relevance, and that efficacy does not differ between the three 
aromatase inhibitors. Therefore, patient preference, tolerability, 
and financial constraints should be considered when choosing 
which schedule and which aromatase inhibitor to include in the 
therapeutic plan for adjuvant hormonal treatment of 
postmenopausal patients with early breast cancer.
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completed before enrolment. Patients with any HER2 
status were eligible, although those with HER2-positive 
tumours had to be treated with trastuzumab according to 
the authorised schedule.
Patients were excluded in cases of hormone-
replacement therapy either at or during the month 
before randomisation; recurrent or metastatic disease 
discovered during baseline staging; HER2-positive 
tumours if treatment with trastuzumab was not feasible; 
previous treatment with tamoxifen; another malignancy 
(breast cancer or invasive cancer other than basal-cell 
carcinoma of the skin or carcinoma in situ of the cervix) 
in the previous 10 years; concomitant severe disease 
that contraindicated adjuvant endocrine treatment or 
would place the patient at high risk of toxicity with the 
study drugs; and treatment with other experimental 
drugs either at or during the month before 
randomisation.
All participants provided written informed consent. 
The protocol was approved by the ethics committees at 
each of the participating institutions. The trial met 
requirements of the Italian Drug Agency for independent 
clinical trials planned to improve clinical practice. The 
study protocol is in the appendix.
Randomisation and masking
Patients were equally allocated (in a 1:1:1:1:1:1 ratio) to one 
of the six study groups via centralised web-based 
randomisation hosted on the GIM group website with a 
computerised minimisation procedure stratified for 
oestrogen receptor and progesterone receptor status (both 
positive vs one positive and one negative vs one positive 
and one unknown), HER2 status (positive [defined as 3+ at 
immunohistochemistry or positive by fluorescence in-situ 
hybridisation] vs negative vs unknown), previous 
chemotherapy (none vs adjuvant vs neoadjuvant vs ajuvant 
and neoadjuvant), and pathological nodal status (pN0 vs 
pN1 vs pN2 vs pN3). This trial was open label, and patients 
and clinical staff were aware of treatment assignment. 
Individuals who did the statistical analyses were masked to 
treatment allocation.
Procedures
Patients received oral anastrozole (1 mg), exemestane 
(25 mg), or letrozole (2·5 mg) tablets once per day for 
5 years (upfront strategy) or once per day for 3 years 
after 2 years of treatment with oral tamoxifen tablets 
(20 mg once per day; switch strategy). All study drugs 
were included in the Italian national formulary and 
reimbursed by the National Health System. Treatment 
could be temporarily suspended because of side-effects 
or other intercurrent reasons. The length of treatment 
interruption was not limited a priori, but it was advised 
to be as short as possible. If the same treatment could 
not be resumed, patients definitively interrupting 
tamoxifen were switched to the aromatase inhibitor 
that had been assigned at randomisation, whereas 
patients interrupting aromatase inhibitors could receive 
tamoxifen as alternative treatment, with a switch to 
a different aromatase inhibitor being prohibited. 
For the GIM group website see 
https://www.oncotech.org/gim/
home/
1847 in the upfront group
1847 included in efficacy analysis
1766 included in safety analysis
1850 in the switch group
1850 included in efficacy analysis
1761 included in safety analysis
3697 pooled according to treatment schedule 3697 pooled according to aromatase inhibitor
3697 patients randomly assigned
615 assigned to
letrozole
34 protocol
  deviations
3 ineligible
29 did not start 
any treatment
2 did not start 
the assigned
treatment
1238 received exemestane
1238 included in efficacy analysis
1177 included in safety analysis
1226 received anastrozole
1226 included in efficacy analysis
1175 included in safety analysis
1233 received letrozole
1233 included in efficacy analysis
1175 included in safetyanalysis
617 assigned to
exemestane
32 protocol 
 deviations
3 ineligible
28 did not start 
any treatment
1 did not start 
the assigned
treatment
615 assigned to
anastrozole
17 protocol 
 deviations
1 ineligible
14 did not start 
any treatment
2 did not start 
the assigned
treatment
618 assigned to
tamoxifen followed
by letrozole
27 protocol 
 deviations
5 ineligible
20 did not start 
any treatment
2 did not start 
the assigned
treatment
621 assigned to
tamoxifen followed
by exemestane
36 protocol 
 deviations
2 ineligible
29 did not start 
any treatment
5 did not start 
the assigned
treatment
611 assigned to
tamoxifen followed
by anastrozole
31 protocol 
 deviations
2 ineligible
26 did not start 
any treatment
3 did not start 
the assigned
treatment
Figure 1: Trial profile
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Permanent discontinuation could occur according to 
investigator’s clinical judgment, unacceptable toxicity, 
patient’s choice, or disease recurrence.
If indicated according to standard guidelines, 
locoregional radiotherapy was administered either before 
or after randomisation, concurrently with the study drugs. 
Trastuzumab was prescribed to patients with HER2-
positive tumours, according to accepted schedule and 
indication. Hormone replacement therapy was prohibited. 
Bisphosphonates were not allowed prophylactically to 
prevent osteoporosis, but could be prescribed to treat 
osteoporosis, if indicated, according to current practice.
Baseline staging included physical examination, blood 
chemistry, and electrocardiogram (ECG) within 1 month 
before randomisation; chest radiograph and liver 
ultrasound or CT scan within 3 months before 
randomisation; and mammography and bone scan 
within 1 year before randomisation. During treatment, 
visits and blood chemistry were planned every 6 months 
up to 5 years after randomisation, then yearly; chest 
radiograph and liver ultrasound or CT scans were 
planned every 6 months for 3 years, then yearly; and 
ECG, mammography, and bone scan were planned 
yearly. Gynaecological examination and measurement of 
bone mineral density were left to the choice of 
investigators at participating centres, but data were 
collected.
Outcomes
The primary endpoint was disease-free survival, defined 
according to the Standardized Definitions for Efficacy 
End Points (STEEP) system13 as the time from 
randomisation to locoregional or distant recurrence, 
contralateral invasive breast cancer, ductal carcinoma in 
situ, second malignancy other than breast, or death from 
any cause (whichever occurred first). No central review 
was done. Secondary endpoints reported in this 
paper are overall survival, defined as the time from 
randomisation to death from any cause, and toxicity, 
assessed according to Common Terminology Criteria for 
Adverse Events version 3.0. Toxicity was assessed at every 
visit for 5 years. Other secondary efficacy endpoints 
according to the STEEP system (ie, invasive-disease-free 
survival, distant-disease-free survival, distant-recurrence-
free survival, relapse-free survival, recurrence-free 
interval, breast-cancer-free interval, distant-recurrence-
free interval) and the effects of treatment on lipid profile 
will be reported separately when a greater number of 
events have been recorded.
Statistical analysis
We calculated sample size using EAST software version 5, 
assuming that a 2% difference in disease-free survival at 
5 years was the minimum clinically significant cutoff 
required to conclude that the upfront strategy was more 
effective than the switch strategy. At initial planning in 
July, 2006, based on comparisons of the switch strategy 
versus upfront tamoxifen, the expected 5-year disease-
free survival with the switch strategy was estimated to be 
85%, corresponding to a hazard ratio (HR) of 0·86. 
Therefore, with a two-sided α value of 0·05, a power 
of 80%, and on the basis of one interim futility analysis, 
1354 events were required and enrolment of about 
10 000 patients was planned. In 2009, after presentation 
of long-term data from the ABCSG trial 8 at the 2008 
San Antonio Breast Cancer Symposium, the expected 
5-year disease-free survival in the switch group was 
increased to 90% (protocol amendment 1; October, 2009) 
and the HR decreased to 0·79. With a two-sided p value of 
0·05, a power of 80%, and on the basis of three interim 
futility analyses, a maximum of 669 events was required 
Treatment schedule Aromatase inhibitor
Switch 
(n=1850)
Upfront 
(n=1847)
Anastrozole 
(n=1226)
Exemestane 
(n=1238)
Letrozole 
(n=1233)
Age, years
Median (IQR) 64 (58–70) 64 (57–70) 64 (58–70) 64 (58–70) 63 (58–71)
<60 556 (30%) 596 (32%) 391 (32%) 365 (29%) 396 (32%)
60–69 768 (42%) 742 (40%) 504 (41%) 523 (42%) 483 (39%)
≥70 526 (28%) 509 (28%) 331 (27%) 350 (28%) 354 (29%)
Type of menopause
>60 years or 
oophorectomy
1309 (71%) 1271 (69%) 842 (69%) 885 (71%) 853 (69%)
<60 years and >1 year 
amenorrhoea
398 (22%) 432 (23%) 296 (24%) 248 (20%) 286 (23%)
<60 years and <1 year 
amenorrhoea*
75 (4%) 69 (4%) 47 (4%) 45 (4%) 52 (4%)
<60 years, unknown 
amenorrhoea
68 (4%) 75 (4%) 41 (3%) 60 (5%) 42 (3%)
Body-mass index
Median (IQR), kg/m² 27·0 
(24·0–30·8)
26·6 
(23·9–30·4)
26·8 
(24·0–30·8)
26·6 
(23·8–30·4)
27·0 
(23·9–30·8)
Underweight or normal 503 (27%) 528 (29%) 326 (27%) 366 (30%) 339 (27%)
Overweight 537 (29%) 568 (31%) 388 (32%) 357 (29%) 360 (29%)
Obese 432 (23%) 410 (22%) 285 (23%) 269 (22%) 288 (23%)
Unknown 378 (20%) 341 (18%) 227 (19%) 246 (20%) 246 (20%)
Hormone receptor (oestrogen receptor and progesterone receptor) status
Both positive 1646 (89%) 1642 (89%) 1094 (89%) 1099 (89%) 1095 (89%)
Only one positive 204 (11%) 205 (11%) 132 (11%) 139 (11%) 138 (11%)
HER2 status
Negative 1663 (90%) 1669 (90%) 1105 (90%) 1114 (90%) 1113 (90%)
Positive 168 (9%) 162 (9%) 107 (9%) 114 (9%) 109 (9%)
Unknown 19 (1%) 16 (1%) 14 (1%) 10 (1%) 11 (1%)
Pathological nodal status
pN0 1191 (64%) 1187 (64%) 788 (64%) 799 (65%) 791 (64%)
pN1 465 (25%) 463 (25%) 311 (25%) 308 (25%) 309 (25%)
pN2 or pN3 194 (10%) 197 (11%) 127 (10%) 131 (11%) 133 (11%)
Pathological tumour category
pT1 1299 (70%) 1287 (70%) 863 (70%) 856 (69%) 867 (70%)
pT2 446 (24%) 447 (24%) 296 (24%) 306 (25%) 291 (24%)
pT3 or pT4 45 (2%) 46 (2%) 33 (3%) 24 (2%) 34 (3%)
Unknown 60 (3%) 67 (4%) 34 (3%) 52 (4%) 41 (3%)
(Table 1 continues on next page)
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and a sample size of 3600 patients was planned. Interim 
futility analyses were planned to reject the alternative 
hypothesis only, according to a β-spending function with 
a Pocock boundary. Applying the same parameters, 
792 events were required for the log-rank comparison of 
the three aromatase inhibitors, according to the Ahnn 
and Anderson approach.14 We focused on main effects 
rather than on interaction because there was no 
suggestion in published literature that schedule effect 
would change across aromatase inhibitors. We planned to 
compare the aromatase inhibitors when the result of the 
primary comparison between schedules became available. 
The first futility interim analysis, done in May, 2015, 
with 318 events, did not lead to early stopping of the trial. 
In 2015, after publication of the Early Breast Cancer 
Trialists’ Collaborative Group (EBCTCG) meta-analysis,15 
and because of the length of time still required to reach 
the planned number of events, the independent data 
monitoring committee suggested that we do the two final 
analyses at a median follow-up of 5 years, independently 
of the number of events. Follow-up and data collection, 
however, will continue, with no defined closure date.
Efficacy analyses were done by intention to treat 
(all randomly assigned patients) and safety analyses 
included all patients for whom at least one safety case 
report form had been completed. In the comparative 
analysis of schedules, we did the primary analysis of 
disease-free survival with a multivariable Cox model 
including stratification variables of hormone receptor 
status, HER2 status, previous chemotherapy, pathological 
nodal status, aromatase inhibitor, and centre size (three 
categories according to tertiles of the number of patients 
enrolled) as covariates. We checked the proportionality 
assumption by entering a time-dependent covariate of 
treatment × log(time) interaction. We tested first-order 
interactions between treatment (schedule [two categories] 
and aromatase inhibitor [three categories] and covariates 
with the likelihood-ratio test of two nested models, with 
and without interaction; the effect of treatments by 
subgroup was reported as HR and 95% CI in a forest plot. 
Such analyses were protocol-specified for stratification 
variables (oestrogen receptor and progesterone receptor 
status, HER2 status, previous chemotherapy, and 
pathological nodal status) or decided post hoc for 
consistency with relevant published literature for age, type 
of menopause, body-mass index, tumour size, histological 
grade, previous trastuzumab, and previous radiotherapy.
For the comparison of the three aromatase inhibitors, 
the global null hypothesis of treatment equivalence had 
to be first tested with the log-rank test; only in case of 
significance at the 0·05 level did we plan to do pairwise 
comparisons between aromatase inhibitors with 
Bonferroni-Holm adjustment.16
Disease-free survival and overall survival were 
estimated with the Kaplan-Meier method.
For toxicity analyses, for each patient and for each type of 
toxicity, we calculated the worst event suffered and reported 
them as the occurrence of either any toxicity (grade 1 or 
worse) or severe toxicity (grade 3 or 4). The complete 
toxicity distribution (ie, all grades suffered) was used for 
statistical comparisons. In both comparisons (strategies 
and aromatase inhibitors), analyses were done with the 
Kruskal–Wallis non-parametric ANOVA with significance 
level of 0·01. If the overall comparison of aromatase 
inhibitors was significant, pairwise comparisons between 
aromatase inhibitors were done with the Kruskal–Wallis 
test using Bonferroni-Holm adjustment; the three α levels 
for sequential testing were 0·0033, 0·005, and 0·01. We 
used Stata/MP for Windows (version 14.2) for all statistical 
analyses.
This study is registered with the European Clinical 
Trials Database, number 2006-004018-42, and 
ClinicalTrials.gov, number NCT00541086.
Role of the funding source
The funder had no role in study design, data collection, 
data analysis, data interpretation, or writing of the report. 
The corresponding author had full access to all the data 
in the study and had final responsibility for the decision 
to submit for publication.
Results
Between March 9, 2007, and July 31, 2012, 3697 eligible 
patients were enrolled at 76 centres in Italy (figure 1). 
Baseline characteristics of patients are summarised by 
treatment schedule strategy and by drug in table 1 and by 
treatment group in the appendix (pp 2–3). Information 
Treatment schedule Aromatase inhibitor
Switch 
(n=1850)
Upfront 
(n=1847)
Anastrozole 
(n=1226)
Exemestane 
(n=1238)
Letrozole 
(n=1233)
(Continued from previous page)
Histological grading
Low 242 (13%) 243 (13%) 169 (14%) 152 (12%) 164 (13%)
Intermediate 1060 (57%) 1069 (58%) 708 (58%) 699 (56%) 722 (59%)
High 407 (22%) 390 (21%) 256 (21%) 281 (23%) 260 (21%)
Unknown 141 (8%) 145 (8%) 93 (8%) 106 (9%) 87 (7%)
Previous chemotherapy
None 1138 (62%) 1144 (62%) 757 (62%) 764 (62%) 761 (62%)
Adjuvant 665 (36%) 658 (36%) 438 (36%) 444 (36%) 441 (36%)
Neoadjuvant 47 (3%) 45 (2%) 31 (3%) 30 (2%) 31 (3%)
Previous or concurrent trastuzumab
No 1660 (90%) 1663 (90%) 1107 (90%) 1100 (89%) 1116 (91%)
Yes 131 (7%) 126 (7%) 88 (7%) 88 (7%) 81 (7%)
Unknown 59 (3%) 58 (3%) 31 (3%) 50 (4%) 36 (3%)
Previous or concurrent radiotherapy
No 544 (29%) 536 (29%) 394 (32%) 334 (27%) 352 (29%)
Yes 1247 (67%) 1253 (68%) 801 (65%) 854 (69%) 845 (69%)
Unknown 59 (3%) 58 (3%) 31 (3%) 50 (4%) 36 (3%)
Data are n (%), unless otherwise specified. *Postmenopausal follicle-stimulating hormone concentrations.
Table 1: Baseline characteristics
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about baseline metabolic profile, comorbidities, and bone 
health status are also in the appendix (pp 4–6). The 
median age of all enrolled patients was 64 years 
(IQR 58–71), the primary tumour was pT1 in 2586 (70%) 
of 3697 patients; axillary lymph nodes were pathologically 
negative in 2378 (64%), and 330 (9%) of 3697 tumours 
were HER2 positive. Adjuvant or neoadjuvant chemo-
therapy had been given to 1415 (38%) of the patients 
before randomisation. All baseline characteristics were 
well balanced among the study groups.
At a median follow-up of 60 months (IQR 46–72), 
401 disease-free survival events (211 with the switch 
schedule and 190 with the upfront schedule) and 138 deaths 
(80 with the switch schedule and 58 with the upfront 
schedule) had been reported. 53 of the patients who died 
did not have cancer when they died (table 2). 85 patients 
had been diagnosed with second non-breast cancer, five of 
whom were diagnosed after breast cancer recurrence 
(table 2; appendix p 7). Breast cancer was the most frequent 
cause of death, both in patients who received the switch 
treatment (55 [3%] of 1850 patients) and in those treated 
upfront (30 [2%] of 1847 patients).
At 5 years, disease-free survival was 88·5% (95% CI 
86·7–90·0) with the switch schedule and 89·8% 
(88·2–91·2) with upfront treatment (HR 0·89, 95% CI 
0·73–1·08; p=0·23; figure 2A). 5-year overall survival was 
95·3% (95% CI 94·1–96·3) with the switch schedule and 
96·8% (95·7–97·6) with the upfront schedule (HR 0·72, 
95% CI 0·51–1·00; p=0·052; figure 2B).
Disease-free survival at 5 years was 90·0% (95% CI 
87·9–91·7) with anastrozole (124 events), 88·0% 
(85·8–89·9) with exemestane (148 events), and 89·4% 
(87·3–91·1) with letrozole (129 events; p=0·24; figure 3A, 
appendix p 8). Since the overall comparison of the three 
aromatase inhibitors was not significant, pairwise 
comparisons between aromatase inhibitors were not done. 
For description only, the HR for progression or death was 
1·24 (95% CI 0·97–1·57) for exemestane versus anastrozole 
and 1·05 (0·82–1·35) for letrozole versus anastrozole 
(appendix p 10). The interaction test between schedule and 
aromatase inhibitor used was not significant (pinteraction=0·26; 
appendix pp 9–10). At 5 years, overall survival was 
95·9% (95% CI 94·4–97·0) with anastrozole (43 deaths), 
95·7% (94·2–96·8) with exemestane (52 deaths), and 
96·6% (95·3–97·6) with letrozole (43 deaths; p=0·52; 
figure 3B). 
In a prespecified analysis, patient and tumour 
characteristics at baseline did not significantly interact 
with treatment effect (HR of progression or death) in 
either comparison (switch vs upfront strategy or 
anastrozole vs exemestane vs letrozole; appendix pp 9–11).
Median time on tamoxifen was 24 months (IQR 23–25); 
median time on treatment was similar for the three 
aromatase inhibitors (32 months [IQR 28–36] to 
35 months [30–36] in the switch group and 54 months 
[52–60] to 56 months [53–60] in the upfront group; 
appendix p 12). Toxicity was the main reason for early 
treatment interruption (appendix p 13), and was more 
frequent with tamoxifen (204 [11%] of 1850 patients) than 
with aromatase inhibitors (93 [5%] of 1850 patients in the 
switch group and 131 [7%] of 1847 patients in the upfront 
group). Endometrial side-effects were the most frequent 
Treatment schedule Aromatase inhibitor
Switch (n=1850) Upfront (n=1847) Anastrozole (n=1226) Exemestane (n=1238) Letrozole (n=1233)
Disease-free survival event 211 190 124 148 129
Type of first disease-free survival event
Locoregional 30/211 (14%) 26/190 (14%) 12/124 (10%) 30/148 (20%) 14/129 (11%)
Distant 99/211 (47%) 84/190 (44%) 63/124 (51%) 57/148 (39%) 63/129 (49%)
Second breast cancer 13/211 (6%) 16/190 (8%) 12/124 (10%) 11/148 (7%) 6/129 (5%)
Second non-breast cancer 44/211 (21%) 36/190 (19%) 26/124 (21%) 29/148 (20%) 25/129 (19%)
Death without any cancer 25/211 (12%) 28/190 (15%) 11/124 (9%) 21/148 (14%) 21/129 (16%)
Second non-breast cancers
Colorectal 9 13 8 7 7
Endometrial 10 3 4 4 5
Pulmonary 3 5 4 2 2
Pancreatic 5 2 3 3 1
Haematological 3 3 1 4 1
Renal 3 2 2 1 2
Ovarian 4 1 1 1 3
Hepatic 4 0 1 2 1
Melanoma 2 1 0 2 1
Urinary 1 2 0 2 1
Other 3 6 3 4 2
Deaths 80 58 43 52 43
Table 2: Distribution of events
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reason for tamoxifen interruption (66 [4%] of 
1850 patients), whereas musculoskeletal side-effects were 
the main reason for interruption of aromatase inhibitors 
(53 [3%] of 1850 patients in the switch group and 76 [4%] of 
1847 patients in the upfront group).
Toxicity data were not available for 170 (5%) of 
3697 patients, and the proportion of missing data was 
similar across comparison groups (appendix pp 14–19). 
Details of toxicity data by treatment group are reported in 
the appendix (pp 14–19). No unexpected serious adverse 
events or treatment-related deaths occurred. Tables 3 
and 4 summarise toxicity data by comparison group, 
according to planned significance rules. Musculoskeletal 
side-effects (including osteo porosis, arthritis, muscle 
weakness, pain) were the most frequent grade 3–4 events, 
reported in 130 (7%) of 1761 patients in the switch group 
and 128 (7%) of 1766 patients in the upfront group. The 
overall frequency of musculoskeletal events (ie, including 
grades 1 and 2) was significantly different between the 
switch and upfront groups because of a higher incidence 
of grade 1 events in the upfront group than in the switch 
group (924 [52%] of 1766 patients vs 745 [42%] of 
1761 patients). Apart from muscoloskeletal events, all 
other grade 3–4 events occurred in less than 2% of 
patients in either group; grade 3–4 cardiac side-effects 
were reported in 19 (1%) of 1761 patients in the switch 
group and in 23 (1%) of 1766 patients in the upfront 
group. Overall, hot flushes, hypertriglyceridaemia, and 
vaginal, vascular, and endometrial adverse events were 
more frequent with the switch schedule than with the 
upfront schedule, whereas hypercholesterolaemia and 
neurological symptoms were more frequent with the 
upfront schedule than with the switch schedule (table 3). 
Bone fractures were reported in 95 (5%) of 1761 patients 
in the switch group and in 74 (4%) of 1766 patients in the 
upfront group (table 3; appendix pp 14–19). Additionally, 
when analysing adverse events by type of aromatase 
inhibitor, gastrointestinal side-effects were more frequent 
with exemestane than with letrozole, and hyper chol-
esterolaemia was more frequent with anastrozole and 
letrozole than with exemestane (table 4). All other side-
effects were not significantly different among the three 
aromatase inhibitors.
Discussion
In this trial, we investigated whether upfront treatment 
(ie, 5 years of aromatase inhibitors) was more effective 
than a switch schedule, wherein aromatase inhibitors 
were administered after 2 years of tamoxifen. We did 
not find upfront treatment to be superior to the switch 
schedule, assuming a minimum clinically significant 
difference in 5-year disease-free survival of 2%. The 
absolute difference between the disease-free-survival 
curves during the 5 years did not reach the 2% threshold, 
with a maximum difference between the groups of 
1·6% after 2 years. Additionally, we did not find significant 
heterogeneity in schedule effect across major patient 
subgroups. The number of deaths and other breast-
related events was too low to allow reliable conclusions to 
be drawn on endpoints other than disease-free survival.
Two other trials of direct comparisons of upfront 
versus sequential treatment were published while 
FATA-GIM3 was ongoing: one with letrozole (the 
BIG 1-98 trial)17 and one with exemestane (the TEAM 
trial).18,19 Neither trial found a significant difference 
between the two schedules, and both studies concluded 
that either strategy is an appropriate treatment option. 
However, the EBCTCG meta-analysis15 of these two trials 
plus another small study done in Italy found that 
disease-free survival was significantly different between 
the strategies, in favour of the upfront strategy, although 
with a small absolute benefit (1·1% at 5 years of 
follow-up, declining to 0·7% at 7 years; HR 0·90, 95% CI 
Figure 2: Disease-free survival (A) and overall survival (B) according to schedule
HR=hazard ratio.
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0·81–0·99; p=0·045). We argue that such absolute 
differences are not clinically relevant. Therefore, 
physicians might reasonably present 5 years of 
aromatase inhibitors or 2 years of tamoxifen then 
aromatase inhibitors up to 5 years as similarly effective 
strategies and discuss with the patient the toxicity 
profile as a possible driver of choice. Our data confirm 
that musculoskeletal symptoms are the most common 
side-effects of aromatase inhibitors, occurring in more 
than half of patients and more frequently with the 
upfront schedule than with the switch schedule because 
of longer exposure to aromatase inhibitors. The 
opportunity to include patient preference and tolerability 
of therapy in the decision-making process was also 
highlighted by the 2017 St Gallen panelists,20 given the 
overall modest differences in outcomes between 
tamoxifen and aromatase inhibitors.
To our knowledge, FATA-GIM3 is the first trial to directly 
compare the three aromatase inhibitors anastrozole, 
exemestane, and letrozole as adjuvant treatments for 
hormone receptor-positive breast cancer. We found no 
significant difference in the three-group comparisons 
and, therefore, did not proceed to formal head-to-head 
pairwise comparisons. The absence of significant 
heterogeneity in treatment effect across major patient 
subgroups does not support any choice of aromatase 
inhibitor based on differential prognostic prediction.
Our data are consistent with those from two large 
prospective trials21,22 that did head-to-head comparisons of 
anastrozole and exemestane or letrozole, with anastrozole 
as the control group. In the MA.27 trial21 in 7576 patients, 
no advantage for exemestane over anastrozole in the event-
free-survival analysis was observed; however, there were 
differences in side-effects, with fewer reports of 
osteoporosis or osteopenia, hypertriglyceridaemia, vaginal 
bleeding, and hypercholestero laemia in patients on 
exemestane than in those on anastrozole, and liver 
function abnormalities and rare episodes of atrial 
fibrillation being less frequent on anastrozole than on 
exemestane. In the FACE trial22 in 4136 patients with 
metastatic axillary nodes, letrozole was not superior to 
anastrozole in terms of disease-free survival or overall 
survival, and no difference was found in terms of toxicity. 
Our data are also consistent with indirect comparisons 
reported in the EBCTCG meta-analysis,15 in which the 
recurrence rate ratios or anastrozole, exemestane, and 
letrozole compared with tamoxifen were 0·71, 0·67, and 
0·73, respectively, suggesting they were similarly effective. 
Few of the side-effects were significantly different between 
the three aromatase inhibitors in our study, which did not 
allow for definition of distinct patterns and are not useful 
to guide decisions in clinical practice.
This study has several strengths. First, the results are 
consistent with findings of the EBCTCG meta-analysis15 
and reinforce the clinical interpretation that aromatase 
inhibitors have minimal benefit over tamoxifen during 
the first 2 years of treatment. Second, to our knowledge, 
FATA-GIM3 is the only trial to compare upfront 
treatment with a switch strategy using anastrozole, and 
the first trial to directly compare the three aromatase 
inhibitors; thus, contributing to the knowledge base, 
which is currently limited to indirect comparisons of the 
EBCTCG meta-analysis and two head-to-head trials, one 
of which was limited to node-positive patients. Third, the 
findings are generalisable given that simple and inclusive 
eligibility criteria were used and that the trial was done in 
a setting highly similar to clinical practice. As expected 
given that this study was done more recently than the 
other trials discussed here, the patient population 
enrolled in FATA-GIM3 is slightly older and has a better 
prognostic profile in terms of pathological nodal status 
and tumour size than patients in the TEAM and BIG1-98 Figure 3: Disease-free survival (A) and overall survival (B) according to aromatase inhibitor
A
Number at risk
(number censored)
Anastrozole
Exemestane
Letrozole
0
p=0·24
1 2 3 4 5 6 7 8 9
1226
(0)
1238
(0)
1233
(0)
1149
(55)
1140
(74)
1142
(67)
1089
(83)
1078
(99)
1077
(105)
1013
(141)
995
(157)
985
(169)
840
(295)
817
(312)
819
(316)
546
(575)
551
(561)
553
(569)
289
(822)
281
(818)
270
(842)
127
(978)
121
(971)
118
(989)
18
(1084)
19
(1072)
25
(1079)
1
(1101)
2
(1088)
1
(1103)
0
10
20
30
40
50
60
70
80
90
100
Di
se
as
e-
fre
e 
su
rv
iv
al
 (%
)
B
Number at risk
(number censored)
Anastrozole
Exemestane
Letrozole
0
p=0·52
1 2 3 4 5 6 7 8 9
1226
(0)
1238
(0)
1233
(0)
1164
(57)
1155
(77)
1159
(70)
1127
(88)
1115
(107)
1102
(114)
1056
(157)
1033
(178)
1021
(189)
875
(322)
851
(350)
851
(350)
571
(616)
581
(614)
579
(619)
301
(884)
300
(889)
283
(908)
133
(1052)
133
(1054)
125
(1066)
21
(1162)
20
(1166)
26
(1164)
1
(1182)
2
(1184)
1
(1189)
Time since randomisation (years)
0
10
20
30
40
50
60
70
80
90
100
O
ve
ra
ll 
su
rv
iv
al
 (%
)
Anastrozole
Exemestane
Letrozole
Articles
www.thelancet.com/oncology   Published online February 23, 2018   http://dx.doi.org/10.1016/S1470-2045(18)30116-5 9
studies.17–19 Fourth, FATA-GIM3 was funded solely by 
academic support, thus enabling us to do a a three-drug 
comparison. Finally, centralised randomisation and 
intention-to-treat analyses preserved similarity of the 
comparison groups, and the proportions of patients lost 
to follow-up were low and similar among treatment 
groups, so that any selection bias seems unlikely.
The main limitation of this study was that the number 
of events, lower than planned, led to underpowered 
comparisons; the actual power of the analysis 
comparing the two schedules was reduced to 0·59. This 
reduction happened mainly because enrolment was 
slower than planned (accrual took 64 months instead of 
36 months), while the observed 5-year disease-free 
survival in the switch group was only slightly less than 
assumed in the sample size definition (88·5% vs 90%). 
However, the proportion of patients who had a primary 
event was consistent with other relevant trials, both 
when considering events related to breast cancer (7·2% 
vs 6·1–10·4%18,19,21) and when considering non-breast 
malignancies (3·6% vs 3·1–4·5%17,21). The FACE trial,22 
which included only node-positive patients, reported a 
higher proportion of events (17·1%) than reported here. 
Furthermore, the first analysis of the TEAM trial19 
reported a larger proportion of breast cancer-related 
events than reported here (10·4% vs 7·2%). Moreover, 
the follow-up of FATA-GIM3 (60 months) is within the 
range of other studies (49–71 months);18,19,21 TEAM17 was 
the only trial to report a longer follow-up period 
(10 years). These similarities suggest that, even if 
comparisons in FATA-GIM3 were underpowered, 
analyses have been done at a reasonable time and with 
mature data.
Another possible study limitation is the fact that 
patients and physicians were not masked to treatment 
assignment; however, statistical analyses were done by 
individuals masked to treatment assignment and, thus, 
information bias should be minimal.
Follow-up procedures in FATA-GIM3 were more 
intensive than recommended in clinical practice 
guidelines. This decision was made to avoid a minimal 
follow-up strategy impeding the chance of finding a 
difference between the groups. Such an approach is 
consistent with the 2006 American Society of Clinical 
Oncology guidelines,23 which state that follow-up 
procedures in clinical trials designed to compare or 
validate treatment approaches might be different from 
those indicated for clinical practice.
The relevance of FATA-GIM3 might be considered low, 
because its results are consistent with previous evidence 
and come after other publications addressing the same 
questions. However, relevance has to be judged at the 
time of the clinical trial design and not post hoc on the 
basis of the observed results. Otherwise, trials yielding 
negative results would be considered as non-relevant or 
of low relevance, exaggerating publication bias, 
inconsistent with best practice in clinical research. 
Switch (n=1761) Upfront (n=1766)
Grade 1–2 Grade 3 Grade 4 Grade 1–2 Grade 3 Grade 4
Cardiac arrhythmia 71 (4%) 7 (<1%) 0 77 (4%) 3 (<1%) 0
Supraventricular and 
nodal arrhythmia
33 (2%) 3 (<1%) 0 27 (2%) 2 (<1%) 0
Cardiac general 368 (21%) 16 (1%) 3 (<1%) 342 (19%) 20 (1%) 3 (<1%)
Ischaemia or infarction 6 (<1%) 1 (<1%) 1 (<1%) 8 (1%) 6 (<1%) 3 (<1%)
Hypertension 342 (19%) 11 (1%) 0 317 (18%) 12 (1%) 0
Constitutional 294 (17%) 4 (<1%) 0 283 (16%) 8 (1%) 0
Fatigue 178 (10%) 3 (<1%) 0 166 (9%) 5 (<1%) 0
Weight gain 89 (5%) 1 (<1%) 0 76 (4%) 2 (<1%) 0
Dermatology or skin 128 (7%) 4 (<1%) 0 90 (5%) 5 (<1%) 0
Pruritus 51 (3%) 2 (<1%) 0 33 (2%) 4 (<1%) 0
Dermatology, other 38 (2%) 1 (<1%) 0 33 (2%) 2 (<1%) 0
Endocrine (hot flushes)* 193 (11%) 0 0 145 (8%) 0 0
Gastrointestinal 190 (11%) 6 (<1%) 0 145 (8%) 8 (1%) 0
Constipation 51 (3%) 1 (<1%) 0 37 (2%) 0 0
Gastritis 40 (2%) 2 (<1%) 0 37 (2%) 2 (<1%) 0
Other 46 (3%) 1 (<1%) 0 36 (2%) 4 (<1%) 0
Lymphatics (oedema) 87 (5%) 1 (<1%) 0 66 (4%) 2 (<1%) 0
Metabolic or laboratory 1287 (73%) 23 (1%) 8 (1%) 1357 (77%) 23 (1%) 6 (<1%)
ALT or AST 53 (3%) 3 (<1%) 0 45 (3%) 3 (<1%) 0
Cholesterol† 1035 (59%) 2 (<1%) 3 (<1%) 1154 (65%) 4 (<1%) 5 (<1%)
Glucose 687 (39%) 17 (1%) 1 (<1%) 666 (38%) 14 (1%) 1 (<1%)
Triglyceride‡ 543 (31%) 5 (<1%) 1 (<1%) 458 (26%) 2 (<1%) 0
Musculoskeletal† 745 (42%) 128 (7%) 2 (<1%) 924 (52%) 125 (7%) 3 (<1%)
Osteoporosis§ 248 (14%) 95 (5%) 0 348 (20%) 74 (4%) 0
Arthritis† 429 (24%) 26 (1%) 1 (<1%) 557 (32%) 36 (2%) 2 (<1%)
Muscle weakness or 
pain§
225 (13%) 5 (<1%) 0 286 (16%) 8 (1%) 0
Bone pain† 373 (21%) 13 (1%) 1 (<1%) 458 (26%) 23 (1%) 2 (<1%)
Neurology 205 (12%) 11 (1%) 5 (<1%) 211 (12%) 13 (1%) 3 (<1%)
Depression 101 (6%) 4 (<1%) 0 81 (4%) 5 (<1%) 1 (<1%)
Anxiety 68 (4%) 2 (<1%) 0 55 (3%) 2 (<1%) 0
CNS cerebrovascular 
ischaemia
1 (<1%) 4 (<1%) 5 (<1%) 2 (<1%) 1 (<1%) 2 (<1%)
Other¶ 47 (3%) 3 (<1%) 0 73 (4%) 6 (<1%) 0
Pain 59 (3%) 2 (<1%) 0 62 (4%) 0 0
Headache 33 (2%) 1 (<1%) 0 35 (2%) 0 0
Other 29 (2%) 1 (<1%) 0 33 (2%) 0 0
Pulmonary 28 (2%) 3 (<1%) 0 31 (2%) 5 (<1%) 0
Renal or genitourinary 22 (1%) 0 0 23 (1%) 4 (<1%) 0
Sexual or reproductive 
function†
52 (3%) 0 0 16 (1%) 0 0
Vaginal† 29 (2%) 0 0 6 (<1%) 0 0
Vascular‡ 52 (3%) 14 (1%) 2 (<1%) 36 (2%) 5 (<1%) 0
Thrombosis or 
embolism
20 (1%) 9 (1%) 2 (<1%) 14 (1%) 3 (<1%) 0
Endometrium† 52 (3%) 8 (1%) 0 11 (1%) 1 (<1%) 0
Other event 67 (4%) 10 (1%) 0 66 (4%) 5 (<1%) 1 (<1%)
Data are n (%). Adverse events are reported if grade 1 or 2 adverse events occurred in ≥10% of patients, if grade 3 or 4 
adverse events occurred in any patient, or if the difference between the groups was significant. The absence of a 
footnote indicates that the difference was not significant. ALT=alanine aminotransferase. AST=aspartate 
aminotransferase. *p=0·005. †p<0·0001. ‡p=0·007. §p=0·003. ¶p=0·001.
Table 3: Summary of adverse events by schedule
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FATA-GIM3 was relevant at the time of its planning 
because the upfront strategy (with anastrozole) was about 
to become standard practice after the publication of the 
ATAC study,3 despite indirect comparisons11 suggesting 
that the switch strategy might be more effective than the 
upfront strategy, musculoskeletal and cardiac toxicity 
Anastrozole (n=1175) Exemestane (n=1177) Letrozole (n=1175)
Grade 1–2 Grade 3 Grade 4 Grade 1–2 Grade 3 Grade 4 Grade 1–2 Grade 3 Grade 4
Cardiac arrhythmia 56 (5%) 2 (<1%) 0 45 (4%) 5 (<1%) 0 47 (4%) 3 (<1%) 0
Supraventricular and nodal 
arrhythmia
29 (2%) 1 (<1%) 0 15 (1%) 3 (<1%) 0 16 (1%) 1 (<1%) 0
Cardiac general 246 (21%) 14 (1%) 3 (<1%) 227 (19%) 12 (1%) 2 (<1%) 237 (20%) 10 (1%) 1 (<1%)
Ischaemia or infarction 4 (<1%) 2 (<1%) 3 (<1%) 5 (<1%) 2 (<1%) 1 (<1%) 5 (<1%) 3 (<1%) 0
Hypertension 226 (19%) 10 (1%) 0 215 (18%) 8 (1%) 0 218 (19%) 5 (<1%) 0
Constitutional 200 (17%) 4 (<1%) 0 187 (16%) 5 (<1%) 0 190 (16%) 3 (<1%) 0
Fatigue 128 (11%) 3 (<1%) 0 106 (9%) 3 (<1%) 0 110 (9%) 2 (<1%) 0
Weight gain 47 (4%) 1 (<1%) 0 56 (5%) 2 (<1%) 0 62 (5%) 0 0
Dermatology or skin 65 (6%) 1 (<1%) 0 79 (7%) 3 (<1%) 0 74 (6%) 5 (<1%) 0
Pruritus 22 (2%) 1 (<1%) 0 30 (3%) 1 (<1%) 0 32 (3%) 4 (<1%) 0
Dermatology other 20 (2%) 0 0 32 (3%) 1 (<1%) 0 19 (2%) 2 (<1%) 0
Endocrine (hot flushes) 110 (9%) 0 0 126 (11%) 0 0 102 (9%) 0 0
Gastrointestinal* 113 (10%) 3 (<1%) 0 136 (12%) 8 (1%) 0 86 (7%) 3 (<1%) 0
Nausea 29 (2%) 0 0 36 (3%) 0 0 19 (2%) 0 0
Constipation 25 (2%) 0 0 40 (3%) 1 (<1%) 0 23 (2%) 0 0
Gastritis 29 (2%) 0 0 29 (2%) 3 (<1%) 0 19 (2%) 1 (<1%) 0
Other 28 (2%) 2 (<1%) 0 37 (3%) 2 (<1%) 0 17 (1%) 1 (<1%) 0
Lymphatics (oedema) 57 (5%) 0 0 47 (4%) 2 (<1%) 0 49 (4%) 1 (<1%) 0
Metabolic/laboratory† 904 (77%) 16 (1%) 3 (<1%) 852 (72%) 13 (1%) 3 (<1%) 888 (76%) 17 (1%) 8 (1%)
ALT or AST 33 (3%) 0 0 27 (2%) 4 (<1%) 0 38 (3%) 2 (<1%) 0
Cholesterol‡ 749 (64%) 2 (<1%) 1 (<1%) 696 (59%) 1 (<1%) 1 (<1%) 744 (63%) 3 (<1%) 6 (1%)
Glucose 478 (41%) 16 (1%) 0 429 (36%) 7 (1%) 1 (<1%) 446 (38%) 8 (1%) 1 (<1%)
Triglyceride 342 (29%) 1 (<1%) 0 313 (27%) 2 (<1%) 0 346 (29%) 4 (<1%) 1 (<1%)
Musculoskeletal 558 (47%) 81 (7%) 1 (<1%) 563 (48%) 82 (7%) 2 (<1%) 548 (47%) 90 (8%) 2 (<1%)
Osteoporosis 201 (17%) 52 (4%) 0 196 (17%) 53 (5%) 0 199 (17%) 64 (5%) 0
Arthritis 330 (28%) 19 (2%) 0 331 (28%) 24 (2%) 2 (<1%) 325 (28%) 19 (2%) 1 (<1%)
Muscle weakness or pain 150 (13%) 6 (1%) 0 185 (16%) 1 (<1%) 0 176 (15%) 6 (1%) 0
Bone pain 271 (23%) 12 (1%) 1 (<1%) 278 (24%) 8 (1%) 0 282 (24%) 16 (1%) 2 (<1%)
Neurology 138 (11%) 8 (1%) 0 128 (11%) 8 (1%) 3 (<1%) 150 (13%) 8 (1%) 5 (<1%)
Depression 58 (5%) 3 (<1%) 0 60 (5%) 3 (<1%) 0 64 (5%) 3 (<1%) 1 (<1%)
Anxiety 43 (4%) 1 (<1%) 0 40 (3%) 2 (<1%) 0 40 (3%) 1 (<1%) 0
CNS cerebrovascular 
ischaemia
2 (<1%) 2 (<1%) 0 1 (<1%) 3 (<1%) 3 (<1%) 0 0 4 (<1%)
Other 40 (3%) 3 (<1%) 0 37 (3%) 2 (<1%) 0 43 (4%) 4 (<1%) 0
Pain 37 (3%) 1 (<1%) 0 40 (3%) 1 (<1%) 0 44 (4%) 0 0
Headache 26 (2%) 0 0 19 (2%) 1 (<1%) 0 23 (2%) 0 0
Other 15 (1%) 1 (<1%) 0 23 (2%) 0 0 24 (2%) 0 0
Pulmonary 23 (2%) 2 (<1%) 0 17 (1%) 3 (<1%) 0 19 (2%) 3 (<1%) 0
Renal or genitourinary 20 (2%) 3 (<1%) 0 10 (1%) 0 0 15 (1%) 1 (<1%) 0
Vascular 30 (3%) 6 (1%) 0 29 (2%) 5 (<1%) 1 (<1%) 29 (2%) 8 (1%) 1 (<1%)
Thrombosis or embolism 11 (1%) 5 (<1%) 0 10 (1%) 4 (<1%) 1 (<1%) 13 (1%) 3 (<1%) 1 (<1%)
Endometrium 10 (1%) 5 (<1%) 0 27 (2%) 1 (<1%) 0 26 (2%) 3 (<1%) 0
Other 41 (3%) 5 (<1%) 0 47 (4%) 6 (1%) 0 45 (4%) 4 (<1%) 1 (<1%)
Data are n (%). Adverse events are reported if grade 1 or 2 adverse events occurred in ≥10% of patients, if grade 3 or 4 adverse events occurred in any patient, or if the difference 
between the groups was significant. The absence of a footnote indicates that the difference was not significant. ALT=alanine aminotransferase. AST=aspartate 
aminotransferase. *p=0·0007 in three-drug comparison; p<0·0001 for exemestane vs letrozole. †p=0·002 in three-drug comparison; p=0·004 for exemestane vs anastrozole; 
p=0·002 for exemestane vs letrozole. ‡p=0·0004 in three-drug comparison; p=0·005 for exemestane vs anastrozole; p=0·001 for exemestane vs letrozole.
Table 4: Summary of adverse events by aromatase inhibitor
Articles
www.thelancet.com/oncology   Published online February 23, 2018   http://dx.doi.org/10.1016/S1470-2045(18)30116-5 11
being considered more probable with longer exposure to 
aromatase inhibitors, and the cost of upfront treatment 
being much higher than the cost of the switch strategy. 
Therefore, investigation of whether the strategy that was 
going to become standard practice in the absence of 
direct evidence was actually better than the strategy that 
might be more effective, less toxic, and less expensive 
was warranted. Our results are consistent with findings 
published in the past 10 years and fill some of the 
knowledge gaps (namely a comparison between the 
upfront and switch schedules when anastrozole is used, 
and a direct comparison of the three aromatase inhibitors 
in both node-negative and node-positive patients), 
providing direct evidence in a setting in which only 
indirect evidence has been available.
Finally, findings from FATA-GIM3, combined with 
those from the TEAM and BIG1-98 trials,17–19 have 
implications for the affordability of adjuvant treatment 
for breast cancer worldwide. When the study was 
planned, the cost of 1 day of treatment with aromatase 
inhibitors in Italy was more than ten times higher than 
that with tamoxifen. In the USA, higher costs and 
copayments have been shown to lead to greater 
non-adherence to treatment with aromatase inhibitors 
and adherence has been improved by the increasing 
availability of generic drugs.24 Nevertheless, even in 
countries where generic formulations are available, 
tamoxifen remains the cheapest drug and, because of the 
long duration of adjuvant treatment, a more affordable 
schedule might favour adherence in countries where, or 
in patients for whom, affordability is a concern.
The future direction of clinical research in the adjuvant 
hormonal treatment of breast cancer will inevitably relate 
to treatment duration, given that risk of relapse remains 
high even after 20 years of follow-up, at least for patients 
with poor prognostic factors.25 Therefore, findings 
regarding the possibility of intermittent treatment 
provide new perspectives that might inform future 
clinical trials.26,27
In conclusion, the results of FATA-GIM3 and other 
available evidence suggest that there could be a small but 
not clinically significant advantage in using the upfront 
instead of the switch strategy in adjuvant hormonal 
treatment of post menopausal patients with early breast 
cancer. Furthermore, there is no evidence that differences 
in efficacy exist among the three aromatase inhibitors. 
Therefore, the decision-making process when prescribing 
treatment for postmenopausal women with endocrine-
sensitive breast cancer should take into account patient 
preference, tolerability, and financial constraints when 
the schedule and the aromatase inhibitor to include in 
the therapeutic plan are chosen.
Contributors
SDP, CG, and FP contributed to the study design and data analysis. 
SDP, CG, GA, and FP wrote the manuscript. All authors (apart from 
CG) contributed to data collection. All authors contributed to the data 
interpretation and approved the final manuscript.
Declaration of interests
SDP reports personal fees from Pfizer, AstraZeneca, and Novartis, 
during the conduct of the study, and grants from AstraZeneca, outside 
the submitted work. MDL reports personal fees from Novartis, Roche, 
AstraZeneca, Amgen, Celgene, Pfizer, and Eli Lilly, outside the 
submitted work. GA reports personal fees from Roche, 
GlaxoSmithKline, Amgen, Takeda, Ipsen, Novartis, Eli Lilly, Pfizer, and 
Celgene, outside the submitted work. LDM reports personal fees and 
non-financial support from Roche and Novartis, non-financial support 
from Celgene, and personal fees from Pfizer, Ipsen, Takeda, and Eli Lilly, 
outside the submitted work. FC reports personal fees from Amgen and 
Genomic Health, outside the submitted work. FM reports personal fees 
from AstraZeneca, Novartis, and Roche, outside the submitted work. 
FP reports grants from Italian Drug Agency (AIFA), during the conduct 
of the study, and personal fees from AstraZeneca, Eli Lilly, Roche, Bayer, 
Ipsen, and Bristol-Myers Squibb, outside the submitted work. All other 
authors declare no competing interests.
Acknowledgments
This study is supported by the FARM5K3MEE AIFA grant from the 
Italian Drug Agency.
References
1 Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). 
Effects of chemotherapy and hormonal therapy for early breast 
cancer on recurrence and 15-year survival: an overview of the 
randomised trials. Lancet 2005; 365: 1687–717.
2 Rutqvist LE, Mattsson A. Cardiac and thromboembolic morbidity 
among postmenopausal women with early-stage breast cancer in a 
randomized trial of adjuvant tamoxifen. The Stockholm Breast 
Cancer Study Group. J Natl Cancer Inst 1993; 85: 1398–406.
3 Baum M, Budzar AU, Cuzick J, et al. Anastrozole alone or in 
combination with tamoxifen versus tamoxifen alone for adjuvant 
treatment of postmenopausal women with early breast cancer: 
first results of the ATAC randomised trial. Lancet 2002; 
359: 2131–39.
4 Boccardo F, Rubagotti A, Puntoni M, et al. Switching to anastrozole 
versus continued tamoxifen treatment of early breast cancer: 
preliminary results of the Italian Tamoxifen Anastrozole Trial. 
J Clin Oncol 2005; 23: 5138–47.
5 Thürlimann B, Keshaviah A, Coates AS, et al. A comparison of 
letrozole and tamoxifen in postmenopausal women with early 
breast cancer. N Engl J Med 2005; 353: 2747–57.
6 Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of 
exemestane after two to three years of tamoxifen therapy in 
postmenopausal women with primary breast cancer. 
N Engl J Med 2004; 350: 1081–92.
7 Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole 
in postmenopausal women after five years of tamoxifen therapy for 
early-stage breast cancer. N Engl J Med 2003; 349: 1793–802.
8 Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, 
Tamoxifen, Alone or in Combination) trial after completion of 
5 years’ adjuvant treatment for breast cancer. Lancet 2005; 
365: 60–62.
9 Jakesz R, Jonat W, Gnant M, et al. Switching of postmenopausal 
women with endocrine-responsive early breast cancer to 
anastrozole after 2 years’ adjuvant tamoxifen: combined results of 
ABCSG trial 8 and ARNO 95 trial. Lancet 2005; 366: 455–62.
10 Buzdar AU, Cuzick J. Optimum use of aromatase inhibitors in the 
adjuvant treatment of early breast cancer. J Clin Oncol 2005; 
23: 8544–46.
11 Punglia RS, Kuntz KM, Winer EP, Weeks JC, Burstein HJ. 
Optimizing adjuvant endocrine therapy in postmenopausal women 
with early-stage breast cancer: a decision analysis. J Clin Oncol 2005; 
23: 5178–87.
12 Singletary SE, Allred C, Ashley P, et al. Revision of the American 
Joint Committee on Cancer staging system for breast cancer. 
J Clin Oncol 2002; 20: 3628–36.
13 Hudis CA, Barlow WE, Costantino JP, et al. Proposal for 
standardized definitions for efficacy end points in adjuvant breast 
cancer trials: the STEEP system. J Clin Oncol 2007; 25: 2127–32.
14 Ahnn S, Anderson SJ. Sample size determination for comparing 
more than two survival distributions. Stat Med 1995; 14: 2273–82.
Articles
12 www.thelancet.com/oncology   Published online February 23, 2018   http://dx.doi.org/10.1016/S1470-2045(18)30116-5
15 Dowsett M, Forbes JF, Bradley R, et al. Aromatase inhibitors versus 
tamoxifen in early breast cancer: patient-level meta-analysis of the 
randomised trials. Lancet 2015; 386: 1341–52.
16 Holm S. A simple sequentially rejective multiple test procedure. 
Scand J Statist 1979; 6: 65–70.
17 Mouridsen H, Giobbie-Hurder A, Goldhirsch A, et al. 
Letrozole therapy alone or in sequence with tamoxifen in women 
with breast cancer. N Engl J Med 2009; 361: 766–76.
18 Derks MGM, Blok EJ, Seynaeve C, et al. Adjuvant tamoxifen and 
exemestane in women with postmenopausal early breast cancer 
(TEAM): 10-year follow-up of a multicentre, open-label, randomised, 
phase 3 trial. Lancet Oncol 2017; 18: 1211–20.
19 van de Velde CJ, Rea D, Seynaeve C, et al. Adjuvant tamoxifen and 
exemestane in early breast cancer (TEAM): a randomised 
phase 3 trial. Lancet 2011; 377: 321–31.
20 Curigliano G, Burstein HJ, Winer EP, et al. De-escalating and 
escalating treatments for early-stage breast cancer: the St Gallen 
International Expert Consensus Conference on the Primary 
Therapy of Early Breast Cancer 2017. Ann Oncol 2017; 28: 1700–12.
21 Goss PE, Ingle JN, Pritchard KI, et al. Exemestane versus 
anastrozole in postmenopausal women with early breast cancer: 
NCIC CTG MA.27—a randomized controlled phase III trial. 
J Clin Oncol 2013; 31: 1398–404.
22 Smith I, Yardley D, Burris H, et al. Comparative efficacy and safety 
of adjuvant letrozole versus anastrozole in postmenopausal patients 
with hormone receptor-positive, node-positive early breast cancer: 
final results of the randomized phase III Femara versus Anastrozole 
Clinical Evaluation (FACE) trial. J Clin Oncol 2017; 35: 1041–48.
23 Khatcheressian JL, Wolff AC, Smith TJ, et al. American Society of 
Clinical Oncology 2006 update of the breast cancer follow-up and 
management guidelines in the adjuvant setting. J Clin Oncol 2006; 
24: 5091–97.
24 Hershman DL, Tsui J, Meyer J, et al. The change from brand-name 
to generic aromatase inhibitors and hormone therapy adherence for 
early-stage breast cancer. J Natl Cancer Inst 2014; 106: dju319.
25 Pan H, Gray R, Braybrooke J, et al. 20-year risks of breast-cancer 
recurrence after stopping endocrine therapy at 5 years. 
N Engl J Med 2017; 377: 1836–46.
26 Abderrahman B, Jordan VC. Rethinking extended adjuvant 
antiestrogen therapy to increase survivorship in breast cancer. 
JAMA Oncol 2018; 4: 15–16.
27 Colleoni M, Luo W, Karlsson P, et al. Extended adjuvant intermittent 
letrozole versus continuous letrozole in postmenopausal women 
with breast cancer (SOLE): a multicentre, open-label, randomised, 
phase 3 trial. Lancet Oncol 2018; 19: 127–38.
